Discovering new compounds to target AMPA receptors for Alzheimer's disease treatment
AMPAR ligand discovery for Alzheimer's disease
This study is looking at a new way to see how certain brain receptors, important for learning and memory, work in people with Alzheimer's disease, which could help improve diagnosis and lead to better treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10884088 on NIH RePORTER |
What this research studies
This research focuses on developing a novel imaging agent that targets AMPA receptors in the brain, which are crucial for learning and memory. By using positron emission tomography (PET), the study aims to visualize and quantify the activity of these receptors in living patients, providing insights into their role in Alzheimer's disease. The goal is to enhance our understanding of how these receptors function in the context of neurodegeneration and to support the development of new therapies. Patients may benefit from improved diagnostic tools and potential new treatments that target AMPA receptor dysfunction.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those showing early signs of cognitive decline.
Not a fit: Patients with other forms of dementia or cognitive impairment unrelated to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better diagnostic methods and new therapeutic options for patients with Alzheimer's disease.
How similar studies have performed: While there have been attempts to develop imaging agents for AMPA receptors, this specific approach is novel and has not been successfully demonstrated in clinical settings.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Liang, Steven H — Emory University
- Study coordinator: Liang, Steven H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.